seekingalpha.com
Fiserv: Accumulating Through A Transition, Not Timing A Bottom
Fiserv shares have overreacted to Q3 2025 guidance and management changes, presenting a patient buy opportunity. Current valuations price in excessive pessimism, assuming permanently impaired margins and low single-digit growth, which my DCF analysis finds unlikely. Core assets remain resilient: Clover GPV grows double digits, client attrition is minimal, and free cash flow guidance is unchanged despite reinvestment.
